Metabolomic tools used in marine natural product drug discovery

被引:42
|
作者
Stuart, Kevin Andrew [1 ]
Welsh, Keira [1 ]
Walker, Molly Clare [1 ]
Edrada-Ebel, RuAngelie [1 ]
机构
[1] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland
关键词
Secondary metabolomics; marine natural products; antibiotics; anti-cancer drugs; NMR; MS; drug discovery; molecular networking; multivariate analysis; MASS-SPECTROMETRY DATA; HYPHENATED NMR METHODS; BREAST-CANCER CELLS; MOLECULAR NETWORKING; ANTIBIOTIC PRODUCTION; HPLC-NMR; TUBULIN POLYMERIZATION; MULTIVARIATE-ANALYSIS; SECONDARY METABOLITE; DRIVEN DISCOVERY;
D O I
10.1080/17460441.2020.1722636
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The marine environment is a very promising resource for natural product research, with many of these reaching the market as new drugs, especially in the field of cancer therapy as well as the drug discovery pipeline for new antimicrobials. Exploitation for bioactive marine compounds with unique structures and novel bioactivity such as the isoquinoline alkaloid; trabectedin, the polyether macrolide; halichondrin B, and the peptide; dolastatin 10, requires the use of analytical techniques, which can generate unbiased, quantitative, and qualitative data to benefit the biodiscovery process. Metabolomics has shown to bridge this understanding and facilitate the development of new potential drugs from marine sources and particularly their microbial symbionts. Areas covered: In this review, articles on applied secondary metabolomics ranging from 1990-2018 as well as to the last quarter of 2019 were probed to investigate the impact of metabolomics on drug discovery for new antibiotics and cancer treatment. Expert opinion: The current literature review highlighted the effectiveness of metabolomics in the study of targeting biologically active secondary metabolites from marine sources for optimized discovery of potential new natural products to be made accessible to a R&D pipeline.
引用
收藏
页码:499 / 522
页数:24
相关论文
共 50 条
  • [41] Natural product derived privileged scaffolds in drug discovery
    Brimble, Margaret
    Davison, Emma
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [42] Natural product hybrids as new leads for drug discovery
    Tietze, LF
    Bell, HP
    Chandrasekhar, S
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (34) : 3996 - 4028
  • [43] Sustainable development of natural product research in drug discovery
    Wang, Y.
    PLANTA MEDICA, 2008, 74 (09) : 897 - 897
  • [44] Natural product drug discovery in the artificial intelligence era
    Saldivar-Gonzalez, F. I.
    Aldas-Bulos, V. D.
    Medina-Franco, J. L.
    Plisson, F.
    CHEMICAL SCIENCE, 2022, 13 (06) : 1526 - 1546
  • [45] Cheminformatics in Natural Product-Based Drug Discovery
    Chen, Ya
    Kirchmair, Johannes
    MOLECULAR INFORMATICS, 2020, 39 (12)
  • [46] Evolving paradigms for natural-product drug discovery
    Geoffrey A.Cordell
    National Science Review, 2022, 9 (11) : 10 - 11
  • [47] Evolving paradigms for natural-product drug discovery
    Cordell, Geoffrey A.
    NATIONAL SCIENCE REVIEW, 2022, 9 (11)
  • [48] Exploring Natural Product Fragments for Drug and Probe Discovery
    Pahl, Axel
    Waldmann, Herbert
    Kumar, Kamal
    CHIMIA, 2017, 71 (10) : 653 - 660
  • [49] Genome Mining and Synthetic Biology in Marine Natural Product Discovery
    Costantini, Maria
    MARINE DRUGS, 2020, 18 (12)
  • [50] In Situ Natural Product Discovery via an Artificial Marine Sponge
    La Clair, James J.
    Loveridge, Steven T.
    Tenney, Karen
    O'Neil-Johnson, Mark
    Chapman, Eli
    Crews, Phillip
    PLOS ONE, 2014, 9 (07):